The use of molecular imaging to bridge the gap between preclinical and clinical investigations of the efficacy of drug therapy and diagnosis and progression of respiratory diseases.
My research is focussed on the development of methods to visualize in situ lung disease and pharmacokinetics and pharmacodynamic properties of inhaled therapies in both animal models of disease and humans, using radiopharmaceuticals and 3-dimensional imaging techniques. Current research involves preclinical molecular imaging of animal models of respiratory disease, including pulmonary fibrosis, COPD, and lung infections, to study disease progression and impact of therapy on disease processes. Clinical imaging studies include cystic fibrosis COPD.
These studies employ techniques in molecular imaging, including positron emission tomography (PET), single photon emission computed tomography (SPECT), and radiopharmaceuticals to measure the pathogenesis of disease as well as drug distribution. Principles of pharmacokinetics are employed to measure the uptake and distribution of the radiopharmaceuticals.